<DOC>
	<DOCNO>NCT00868634</DOCNO>
	<brief_summary>The aim trial detect superiority triple combination capecitabine , bevacizumab vinorelbine versus combination capecitabine bevacizumab patient metastatic breast cancer . 600 patient , 300 treatment group , treat progression disease determine PFS .</brief_summary>
	<brief_title>Capecitabine Bevacizumab Â± Vinorelbine Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Key Written inform consent . Able comply protocol . ECOG Performance status 0 2 . Life expectancy 12 week . Known ER / PR status . Confirmed HER2/neunegative , adenocarcinoma breast measurable nonmeasurable locally recurrent metastatic disease , candidate chemotherapy . Previous ( neo ) adjuvant chemotherapy allow provide last dose chemotherapy apply 6 month prior randomization . Previous adjuvant radiotherapy allow part treatment early breast cancer provide 30 % marrowbearing bone irradiate . No sign symptom CHF . Adequate hepatic renal function value . Adequate hematologic function value . Key Pregnant lactate female . Previous chemotherapy metastatic locally recurrent breast cancer . Previous radiotherapy treatment metastatic disease ( unless give relief metastatic bone pain ) Evidence spinal cord compression current evidence central nervous system ( CNS ) metastases . Major surgical procedure , open biopsy significant traumatic injury within 28 day prior randomization , anticipation need major surgery course study treatment . History evidence inherit bleed diathesis coagulopathy risk bleeding . Uncontrolled hypertension ( systolic &gt; 150 mmHg and/or diastolic &gt; 100 mmHg ) . Clinically significant ( i.e . active ) cardiovascular disease , require medication study might interfere regularity study treatment , control medication . Nonhealing wound , active peptic ulcer bone fracture . History abdominal fistula , grade 4 nongastrointestinal fistula , gastrointestinal perforation intrabdominal abscess within 6 month randomization . Active infection require i.v . antibiotic randomization . Clinically significant malabsorption syndrome inability take oral medication . Known hypersensitivity study drug excipients . Concurrent treatment drug interfere study medication . Concurrent participation another clinical trial . Prior participation allow last study medication apply 4 week prior randomization .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>